Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura

Clinical Therapeutics

Volumn 31, Issue 5, 2009, Pages 1082-1091

  Xie, Feng ^a,b   Blackhouse, Gord ^a,b   Assasi, Nazila ^a,b   Campbell, Kaitryn ^a,b   Levin, Mitchell ^a,b   Bowen, Jim ^a,b   Tarride, Jean Eric ^a,b   Pi, David ^c   Goeree, Ron ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

chronic; cost; immune thrombocytopenic purpura; intravenous immunoglobulin; relapse

Indexed keywords

IMMUNOGLOBULIN; PREDNISONE;

ADULT; AGED; ARTICLE; BLEEDING; CANADA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG RESPONSE; HEALTH CARE SYSTEM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RELAPSE; SPLENECTOMY; STROKE; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CANADA; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; MODELS, ECONOMIC; PREDNISONE; PURPURA, THROMBOCYTOPENIC; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 67049172689     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.05.006     Document Type: Article

References (45)

1. Cines D.B., and Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 346 (2002) 995-1008
2. Frederiksen H., and Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 94 (1999) 909-913
3. Reid M.M. Chronic idiopathic thrombocytopenic purpura: Incidence, treatment, and outcome. Arch Dis Child 72 (1995) 125-128
4. Ou C.Y., Hsieh K.S., Chiou Y.H., et al. A comparative study of initial use of intravenous immunoglobulin and predniso-lone treatments in childhood idiopathic thrombocyto-penic purpura. Acta Paediatr Taiwan 47 (2006) 226-231
5. Treutiger I., Rajantie J., Zeller B., et al., the NOPHO ITP Study Group. Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity?. Arch Dis Child 92 (2007) 704-707
6. Watts R.G. Idiopathic thrombocytopenic purpura: A 10-year natural history study at the Childrens Hospital of Alabama. Clin Pediatr (Phila) 43 (2004) 691-702
7. Godeau B., Lesage S., Divine M., et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 82 (1993) 1415-1421
8. Godeau B., Caulier M.T., Decuypere L., et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: Results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 107 (1999) 716-719
9. Godeau B., Chevret S., Varet B., et al., French ATIP Study Group. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocy-topenic purpura: A randomised, multicentre trial. Lancet 359 (2002) 23-29
10. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic throm-bocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 88 (1996) 3-40
11. Portielje J.E. Response to letter: Mortality in adults with ITP. Blood 98 (2001) 2283
12. Pendergrast J.M., Sher G.D., and Callum J.L. Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995-2000. Vox Sang 89 (2005) 150-160
13. Canadian Blood Services. Availability of IVIG products for 2004-2005. Customer letter #2004-08. http://www.bloodservices.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/r esources/Customer+Letters/$file/CL+2004-08_E pdf. Accessed May 25, 2008
14. Canadian Blood Services. Important information regarding intravenous immune globulin (IVIG): Demand & supply trends and utilization guidelines. http://www.bloodservices.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/r esources/CustomerLetters07/$file/CL2007-06.pdf Accessed May 25, 2008
15. Chen S., Pi D., Ansari M., et al. Polyclonal intravenous im-munoglobulin in patients with immune thrombocytopenic purpura: Clinical systematic review. http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?View=Full&ID=3200800 0112 Accessed May 25, 2008
16. Anderson D., Ali K., Blanchette V., et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 21 Suppl 1 (2007) S9-S56
17. Stasi R., Stipa E., Masi M., et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 98 (1995) 436-442
18. Vianelli N., Valdrè L., Fiacchini M., et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica 86 (2001) 504-509
19. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 126 (1997) 307-314
20. Compendium of Pharmaceuticals and Specialties 2007: The Canadian Drug Reference for Health Professionals (Compendium of Pharmaceuticals and Specialties [Canada]) (2007), Canadian Pharmacists Association, Ottawa, Ontario, Canada
21. Jacobs P., Wood L., and Novitzky N. Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: A prospective randomized clinical trial. Am J Med 97 (1994) 55-59
22. Bourgeois E., Caulier M.T., Delarozee C., et al. Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: A prospective analysis. Br J Haematol 120 (2003) 1079-1088
23. Colovic M., Dimitrijevic M., Sonnenburg C., et al. Clinical efficacy and safety of a novel intravenous immunoglobu-lin preparation in adult chronic ITP. Hematol J 4 (2003) 358-362
24. Unsal C., Gurkan E., Guvenc B., et al. Anti-D and intravenous immunoglobulin treatments in chronic idiopathic thrombocytopenic purpura. Turkish J Haematol 21 (2004) 27-32
25. Wang T., Xu M., Ji L., et al. Splenectomy for adult chronic idiopathic thrombocytopenic purpura: Experience from a single center in China. Eur J Haematol 75 (2005) 424-429
26. Wolf H.H., Davies S.V., Borte M., et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: Studies in patients with immune throm-bocytopenic purpura and primary immunodeficiencies. Vox Sang 84 (2003) 45-53
27. Jacobs P., and Wood L. The comparison of gammaglobulin to steroids in treating adult immune thrombocy-topenia. An interim analysis. Blut 59 (1989) 92-95
28. Li H.Q., Zhang L., Zhao H., et al. Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: A retrospective single-centered analysis of 1791 cases. Chin Med J (Engl) 118 (2005) 34-37
29. Neylon A.J., Saunders P.W., Howard M.R., et al., Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients. Br J Haematol 122 (2003) 966-974
30. Vianelli N., Galli M., de Vivo A., et al., Gruppo Italiano per lo Studio delle Malattie Ematologiche dell'Adulto. Efficacy and safety of splenectomy in immune thrombocy-topenic purpura: Long-term results of 402 cases. Haematologica 90 (2005) 72-77
31. Government of Canada. Life tables, Canada, provinces and territories. http://dsp-psd.tpsgc.gc.ca/Collection/Statcan/84-537-X/84-537-XIE.html Accessed May 25, 2008
32. Cohen Y.C., Djulbegovic B., Shamai-Lubovitz O., and Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160 (2000) 1630-1638
33. Ontario Ministry of Health and Long-Term Care. e-Formulary. Ontario Drug Benefit Formulary/Comparative Drug Index. https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp Accessed May 25, 2008
34. Ministry of Health and Long-Term Care. Ontario Case Costing Initiative. https://ospace.scholarsportal.info/bitstream/1873/12700/1/284279.pdf Accessed May 25, 2008
35. Kind P., Hardman G., and Macran S. UK Population Norms for EQ-5D (1999), University of York Centre for Health Economics, York, UK
36. Briggs A.H., Goeree R., Blackhouse G., and O'Brien B.J. Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 22 (2002) 290-308
37. Claxton K.P., and Sculpher M.J. Using value of information analysis to prioritise health research: Some lessons from recent UK experience. PharmacoEconomics 24 (2006) 1055-1068
38. Groot Koerkamp B., Myriam Hunink M.G., Stijnen T., and Weinstein M.C. Identifying key parameters in cost-effectiveness analysis using value of information: A comparison of methods. Health Econ 15 (2006) 383-392
39. Brennan A., Kharroubi S., O'hagan A., and Chilcott J. Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. Med Decis Making 27 (2007) 448-470
40. McMillan R., Bussel J.B., George J.N., et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 83 (2008) 150-154
41. Mathias S.D., Bussel J.B., George J.N., et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocy-topenic purpura: Its development and validation. Health Qual Life Outcomes 5 (2007) 11
42. Mathias S.D., Gao S.K., Miller K.L., et al. Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: A conceptual model starting with the patient perspective. Health Qual Life Outcomes 6 (2008) 13
43. Aledort L.M., Salama A., Kovaleva L., et al., the International Anti-D Study Group. Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac) in chronic immune thrombocytopenic purpura. Hematology 12 (2007) 289-295
44. Ramadan K.M., and El-Agnaf M. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopath-ic thrombocytopenic purpura. Clin Lab Haematol 27 (2005) 267-269
45. Scaradavou A., Woo B., Woloski B.M., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood 89 (1997) 2689-2700